Taken together, these data show that sintilimab plus anlotinib has exhibited better anti‐tumor activity than other similar combinations of a multi‐target angiogenesis inhibitor and ICI and shown comparable efficacy to a four‐drug regimen in patients with pre‐treated NSCLC with uncommon EGFR mutations. Here, EGFR is linked to neoplasm.